Mark Stroh

2.4k citations

55 papers · 1.9k indexed · 1 hit paper · h-index 19

Impact in

Microbiology top 5%
- Antimicrobial Peptides and Activities
Biomaterials top 5%

Papers in ⓘ

Oncology 25
- Cancer Immunotherapy and Biomarkers 9
- HER2/EGFR in Cancer Research 7
- CAR-T cell therapy research 4
Pharmacology 6
- Pharmacogenetics and Drug Metabolism 6

Co-authors: Raymond C. Stevens (2 shared papers)Moungi G. Bawendi (2 shared papers)Rakesh K. Jain (2 shared papers)John P. Zimmer (2 shared papers)Yinthai Chan (1 shared paper)Jonathan S. Steckel (1 shared paper)Dan G. Duda (1 shared paper)Tatyana Levchenko (1 shared paper)
Journals: Journal of Clinical Oncology (7 papers)Clinical Pharmacology & Therapeutics (6 papers)Cancer Chemotherapy and Pharmacology (6 papers)American Journal of Therapeutics (4 papers)CPT Pharmacometrics & Systems Pharmacology (3 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Mark Stroh

52 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo 2005 · 322 citations

Peers

Countries citing papers authored by Mark Stroh

Since Specialization

Citations

This map shows the geographic impact of Mark Stroh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Stroh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Stroh more than expected).

Fields of papers citing papers by Mark Stroh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Stroh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Stroh. The network helps show where Mark Stroh may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Stroh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Stroh Line = papers co-authored together Mark Stroh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo Nature Medicine ·Mark Stroh, John P. Zimmer, Dan G. Duda, Tatyana Levchenko, Kenneth S. Cohen, Edward B. Brown, David T. Scadden, Vladimir P. Torchilin, Moungi G. Bawendi, Dai Fukumura, Rakesh K. Jain Hit paper breakdown →	2005	322
2	Cholera Toxin Binding Affinity and Specificity for Gangliosides Determined by Surface Plasmon Resonance Biochemistry ·Geoffrey M. Kuziemko, Mark Stroh, Raymond C. Stevens	1996	272
3	Incorporation of Luminescent Nanocrystals into Monodisperse Core–Shell Silica Microspheres Advanced Materials ·Yinthai Chan, John P. Zimmer, Mark Stroh, Jonathan S. Steckel, Rakesh K. Jain, Moungi G. Bawendi	2004	190
4	A ‘litmus test’ for molecular recognition using artificial membranes Chemistry & Biology ·Deborah H. Charych, Quan Cheng, A. Reichert, Geoffrey M. Kuziemko, Mark Stroh, Jon O. Nagy, Wayne Spevak, Raymond C. Stevens	1996	177
5	Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults The Journal of Clinical Endocrinology & Metabolism ·Ira Gantz, Ngozi Erondu, Madhuja Mallick, Bret J. Musser, Rajesh Krishna, Wesley Tanaka, Karen Snyder, Cathy Stevens, Mark Stroh, Haiyuan Zhu, John A. Wagner, Douglas J. MacNeil, Steven B. Heymsfield, John M. Amatruda	2007	124
6	Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma Clinical Pharmacology & Therapeutics ·Mark Stroh, Helen Winter, Mathilde Marchand, Laurent Claret, Stephen Eppler, Jane Ruppel, Oyewale O. Abidoye, SL Teng, WT Lin, S Dayog, René Bruno, Jiangtao Jin, Sandhya Girish	2016	116
7	Diffusion of Nerve Growth Factor in Rat Striatum as Determined by Multiphoton Microscopy Biophysical Journal ·Mark Stroh, Warren R. Zipfel, Rebecca M. Williams, Watt W. Webb, W. Mark Saltzman	2003	57
8	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics Clinical Cancer Research ·Laurent Claret, Jin Y. Jin, Charles Ferté, Helen Winter, Sandhya Girish, Mark Stroh, Pei He, Marcus Ballinger, Alan Sandler, Amita Joshi, Achim Rittmeyer, D. Gandara, Jean‐Charles Soria, René Bruno	2018	53
9	Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease The Journal of Clinical Pharmacology ·Carol Addy, C. Assaid, David Hreniuk, Mark Stroh, Yang Xu, W. Joseph Herring, Aaron Ellenbogen, Hyder A. Jinnah, Louis Kirby, Mark Leibowitz, R. Malcolm Stewart, Daniel Tarsy, James W. Tetrud, S. Aubrey Stoch, Keith Gottesdiener, John A. Wagner	2009	51
10	Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies Clinical Cancer Research ·Melissa L. Johnson, Anthony B. El-Khoueiry, Navid Hafez, Nehal J. Lakhani, Hirva Mamdani, Jordi Rodón, Rachel E. Sanborn, Javier Garciá Corbacho, Valentina Boni, Mark Stroh, Alison L. Hannah, Song Wang, Henry Castro, Alexander I. Spira	2021	45
11	First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc). Journal of Clinical Oncology ·William R. Schelman, Shahneen Sandhu, Víctor Moreno, G. Wilding, Long Sun, Carlo Toniatti, Mark Stroh, N. Kreischer, Celia L. Carpenter, L. Rhoda Molife, S. B. Kaye, Johann S. de Bono, R.M. Wenham	2011	42
12	A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities Cancer Chemotherapy and Pharmacology ·Dan Lü, Tong Lu, Mark Stroh, Richard Graham, Priya Agarwal, Luna Musib, Chi‐Chung Li, Bert L. Lum, Amita Joshi	2016	41
13	RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice Molecular Pharmacology ·Jie Wei, Jeffrey J. Jones, Jing Kang, Ananda Card, Michael Krimm, Paula J. Hancock, Yi Pei, Brandon Ason, Elmer Payson, Natalya Dubinina, Mark T. Cancilla, Mark Stroh, Julja Burchard, Alan B. Sachs, Jerome Hochman, W. Michael Flanagan, Nelly A. Kuklin	2011	40
14	Multiphoton microscopy guides neurotrophin modification with poly(ethylene glycol) to enhance interstitial diffusion Nature Materials ·Mark Stroh, Warren R. Zipfel, Rebecca M. Williams, Shu Chin, Watt W. Webb, W. Mark Saltzman	2004	31
15	APK/PDAnalysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients Clinical Pharmacology & Therapeutics ·Ida Netterberg, Chi‐Chung Li, Luciana Molinero, Nageshwar Budha, Siddharth Sukumaran, Mark Stroh, E. Niclas Jonsson, Lena E. Friberg	2018	30
16	CX-072 (pacmilimab), a Probody ^® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study Journal for ImmunoTherapy of Cancer ·Aung Naing, Fiona Thistlethwaite, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens, Nataliya V. Uboha, Patrick A. Ott, Patricia LoRusso, Javier García-Corbacho, Valentina Boni, Johanna C. Bendell, Karen A. Autio, Manreet Randhawa, Greg Andrew Durm, Marta Gil-Martín, Mark Stroh, Alison L. Hannah, Hendrik-Tobias Arkenau, Alexander I. Spira	2021	27
17	High-gain excitonic lasing from a single InAs monolayer in bulk GaAs Applied Physics Letters ·A. R. Goñi, Mark Stroh, C. Thomsen, F. Heinrichsdorff, V. Türck, A. Krost, D. Bimberg	1998	26
18	Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer The Oncologist ·Rocio García‐Carbonero, Eric Van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Niall C. Tebbutt, Fadi Braiteh, Guillem Argilés, Zev A. Wainberg, Roel Funke, Maria Anderson, Bruce McCall, Mark Stroh, Eric Wakshull, Priti S. Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Herbert I. Hurwitz	2017	23
19	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study Journal for ImmunoTherapy of Cancer ·Rachel E. Sanborn, Omid Hamid, Elisabeth G.E. de Vries, Patrick A. Ott, Javier García-Corbacho, Valentina Boni, Johanna C. Bendell, Karen A. Autio, Daniel C. Cho, Ruth Plummer, Mark Stroh, Lawrence Lu, Fiona Thistlethwaite	2021	20
20	Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans Xenobiotica ·Christopher R. Gibson, Ping Lü, Cheri M. Maciolek, Christen Wudarski, Zoe Barter, K Rowland‐Yeo, Mark Stroh, Eseng Lai, Deborah A. Nicoll‐Griffith	2013	15

About Mark Stroh

Mark Stroh is a scholar working on Oncology, Pharmacology, Radiology, Nuclear Medicine and Imaging, Immunology and Reproductive Medicine, having authored 55 papers that have together received 1.9k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (10 papers), Cancer Immunotherapy and Biomarkers (9 papers), HER2/EGFR in Cancer Research (7 papers), Immunotherapy and Immune Responses (6 papers), Pharmacogenetics and Drug Metabolism (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers), CAR-T cell therapy research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). The work is most often cited by research in Microbiology (119 citations), Biomaterials (194 citations), Oncology (398 citations), Endocrine and Autonomic Systems (87 citations) and Endocrinology (62 citations). Mark Stroh has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Raymond C. Stevens, Moungi G. Bawendi, Rakesh K. Jain, John P. Zimmer, Yinthai Chan, Jonathan S. Steckel, Dan G. Duda, Tatyana Levchenko, Dai Fukumura and Vladimir P. Torchilin. Their work appears in journals such as Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics, Cancer Chemotherapy and Pharmacology, American Journal of Therapeutics and CPT Pharmacometrics & Systems Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact